A meta-analysis of FDG-PET for the evaluation of breast cancer recurrence and metastases Carmen R. IsasiRenee M. MoadelM. Donald Blaufox Report Pages: 105 - 112
Interleukin-10 promoter polymorphism is associated with decreased breast cancer risk Uwe LangsenlehnerPeter KripplHellmut Samonigg Report Pages: 113 - 115
Clodronate treatment influences MMP-2 associated outcome in node positive breast cancer S. LeppäT. SaartoI. Elomaa Report Pages: 117 - 125
Distinct breast cancer incidence and prognostic patterns in the NCI’s SEER program: suggesting a possible link between etiology and outcome William F. AndersonIsmail JatoiSusan S. Devesa Report Pages: 127 - 137
Complementary and alternative medicine use is associated with an increased perception of breast cancer risk and death Eileen RakovitchJean-Philippe PignolMark Clemons Report Pages: 139 - 148
Genetic polymorphisms of TGF-β1 & TNF-β and breast cancer risk Kyoung-Mu LeeSue Kyung ParkDaehee Kang Report Pages: 149 - 155
A phase II trial of imatinib mesylate monotherapy in patients with metastatic breast cancer Shanu ModiAndrew D. SeidmanClifford A. Hudis Report Pages: 157 - 163
The CHEK2 c.1100delC germline mutation rarely contributes to breast cancer development in the Czech Republic Zdenek KleiblJan NovotnyPetr Pohlreich Report Pages: 165 - 167
Primary docetaxel chemotherapy in patients with breast cancer: impact on response and survival Steven D. HeysTarun SarkarAndrew W. Hutcheon Review Pages: 169 - 185
Pathology of breast cancer in women with constitutional CHEK2 mutations Tomasz HuzarskiCezary CybulskiJan Lubiński Brief communication Pages: 187 - 189
Is stereotactic large-core needle biopsy beneficial prior to surgical treatment in BI-RADS 5 lesions? H. M. VerkooijenG. VlastosK. Kinkel-Trugli Letter to the editor Pages: 191 - 191
